• In July 2021, the FDA approved a pioneering biodegradable bronchial stent, designed to safely dissolve over time and reduce the need for removal procedures.

• In August 2024, Renata Medical secured FDA clearance for its Minima Growth Stent, the first expandable lung stent tailored for neonates and infants to address congenital airway disorders.

In this report, the Lung Stents Market has been segmented by Product, Material, Product Type, Procedure, End Users and Geography.

Lung Stents Market, Segmentation by Product

The Lung Stents Market has been segmented by Product into Self-Expandable Stents , Non-Expandable Stents and Balloon-Expandable Stents.

Self-Expandable Stents

Self-Expandable Stents dominate the lung stents market, accounting for approximately 56% of global revenue in 2022. These stents offer flexibility and adaptability to airway anatomy, which makes them suitable for treating both benign and malignant airway obstructions. Their ease of placement and removal, combined with improved patient comfort, supports their widespread adoption in clinical practice.

Non-Expandable Stents

Non-Expandable Stents contribute to around 23% of the lung stents market share. These stents are typically used in specialized cases where rigid support is necessary, providing durable and long-term patency in complex airway obstructions. While less commonly used than other types, they are essential in certain clinical scenarios, ensuring versatility in treatment options.

Balloon-Expandable Stents

Balloon-Expandable Stents hold an estimated 21% share in the lung stents market in 2022. Their precision deployment and ability to achieve high radial force make them suitable for managing localized obstructions. These stents are particularly beneficial in cases requiring controlled expansion, offering targeted relief and reducing the risk of migration.

Lung Stents Market, Segmentation by Material

The Lung Stents Market has been segmented by Material into Metal Lung Stents - [Nitinol Lung Stents, Stainless Steel Lung Stents and Others], Silicone Lung Stents, and Hybrid Lung Stents.

Metal Lung Stents

Metal lung stents are widely used for their durability and radial strength, providing effective airway support in cases of tracheobronchial obstruction. Nitinol lung stents are valued for their shape memory and flexibility, allowing easier placement and adaptation to airway contours. Stainless steel lung stents offer rigid structural support and are ideal for situations requiring permanent stenting. Other metal variants are used based on specific clinical requirements for long-term airway patency.

Silicone Lung Stents

Silicone lung stents are preferred for their biocompatibility and ease of removal, making them ideal for benign airway conditions and temporary interventions. Their non-metallic composition reduces the risk of tissue reaction and enables customized shaping during bronchoscopic placement, offering a patient-friendly alternative to metal stents.

Hybrid Lung Stents

Hybrid lung stents combine the benefits of metal and silicone, offering flexibility, structural integrity, and removability. These stents are increasingly adopted for managing complex airway diseases, where both long-term support and minimized tissue damage are critical. Their innovative design enhances clinical outcomes in both malignant and non-malignant airway obstructions.

Lung Stents Market, Segmentation by Product Type

The Lung Stents Market has been segmented by Product Type into Tracheal Stents, Bronchial Stents, and Others.

Tracheal Stents

Tracheal Stents dominate the lung stents market, accounting for approximately 52% of global revenue in 2022. These stents are widely used to manage tracheal obstructions caused by tumors or strictures. Their durability and flexibility make them a preferred option for maintaining airway patency in critical cases. The ability to effectively manage malignant and benign airway conditions further reinforces their market position.

Bronchial Stents

Bronchial Stents hold an estimated 34% share of the lung stents market. Designed to treat bronchial obstructions, these stents offer targeted support for airway narrowing due to various causes. Their biocompatibility and ability to adapt to the anatomy of the bronchial tree make them essential in comprehensive lung stent procedures.

Others

The "Others" category, which includes specialized lung stents for complex airway scenarios, contributes to around 14% of the lung stents market revenue. These stents are used in highly specialized cases and in innovative research settings, ensuring access to customized airway management solutions. Although their share is smaller, they play a crucial role in addressing unique patient needs.

Lung Stents Market, Segmentation by Procedure

The Lung Stents Market has been segmented by Procedure into Bronchoscopy - [Flexible Bronchoscopy and Rigid Bronchoscopy], and Laryngoscopy.

Bronchoscopy

Bronchoscopy is the most common procedure for the placement of lung stents, enabling direct visualization and access to the airways. Flexible bronchoscopy is widely used due to its minimally invasive nature and ability to navigate complex airway structures, making it ideal for diagnostic and therapeutic stent placement. Rigid bronchoscopy, though more invasive, offers better control in managing severe obstructions and is preferred in cases requiring larger stents or significant airway intervention.

Laryngoscopy

Laryngoscopy is employed for airway assessment and stent placement when upper airway involvement is suspected. It allows for the evaluation of the larynx and vocal cords and is particularly useful in cases where tumors, strictures, or foreign bodies affect the upper respiratory tract. This procedure supports accurate diagnosis and ensures precise stent positioning in the laryngeal region.

Lung Stents Market, Segmentation by End Users

The Lung Stents Market has been segmented by End Users into Hospitals , Ambulatory Surgery Centers and Others.

Hospitals

Hospitals are the primary end users in the lung stents market, contributing to approximately 59% of revenue in 2022. Equipped with advanced diagnostic and therapeutic facilities, hospitals provide comprehensive care for patients requiring lung stent placement. The presence of skilled medical professionals and specialized pulmonary departments enhances the adoption of lung stents in this segment.

Ambulatory Surgery Centers

Ambulatory Surgery Centers (ASCs) account for around 28% of the lung stents market revenue. These centers offer efficient and cost-effective settings for minimally invasive lung stent procedures. The growing demand for outpatient treatments, combined with shorter recovery times and reduced hospital stays, drives the increasing adoption of lung stents in ASCs.

Others

The "Others" category, including specialty clinics and research institutions, holds an estimated 13% share of the lung stents market. These facilities contribute to the market by offering specialized care for complex airway cases and supporting clinical research on innovative lung stent technologies. Their role in advancing airway management solutions adds valuable diversity to the market.

Lung Stents Market, Segmentation by Geography

In this report, the Lung Stents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Lung Stents Market Share (%), by Geographical Region

North America

North America leads the lung stents market, accounting for approximately 41% of global revenue in 2022. Factors driving growth include a high prevalence of lung diseases, advanced healthcare infrastructure, and strong presence of leading market players. Significant investments in research and development and the adoption of minimally invasive procedures further strengthen the market in this region.

Europe

Europe contributes to around 27% of the lung stents market. The region’s growth is supported by a rising incidence of airway disorders, expanding healthcare expenditure, and increasing adoption of lung stent technologies. Regulatory support and reimbursement frameworks also promote wider market penetration.

Asia Pacific

Asia Pacific holds an estimated 21% share of the lung stents market in 2022. Rapidly improving healthcare infrastructure, rising awareness of airway treatments, and increasing cases of chronic respiratory diseases drive the region’s growth. Countries such as China and India offer significant expansion opportunities due to large patient populations and growing healthcare investments.

Middle East and Africa

Middle East and Africa contribute to approximately 6% of the lung stents market. Growth in this region is primarily driven by improvements in healthcare access and a rising burden of airway diseases. Increased collaboration between healthcare providers and market leaders is enhancing market presence.

Latin America

Latin America accounts for around 5% of the lung stents market. Rising prevalence of respiratory diseases, combined with improving medical infrastructure and growing awareness of minimally invasive treatments, support market growth. Increased healthcare investments and expanding access to advanced airway management solutions further drive the region’s market potential.

This report provides an in depth analysis of various factors that impact the dynamics of Lung Stents Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Rising prevalence of lung-related disorders
• Technological advancements in stent design
• Growing demand for minimally invasive procedures

• Increasing adoption in emerging healthcare markets - Significantly contributing to the growth of the global lung stents market. Countries across Asia-Pacific, Latin America, and the Middle East are investing heavily in healthcare infrastructure development, particularly in improving pulmonology and thoracic care. With rising cases of chronic obstructive pulmonary disease (COPD), lung cancer, and other airway obstructions, the demand for advanced airway management solutions is growing. Healthcare providers in these regions are now more open to adopting minimally invasive technologies, such as lung stents, which are increasingly being seen as viable, life-saving interventions.

  The influx of medical tourism to countries like India, Thailand, and Brazil is also encouraging hospitals to modernize their treatment facilities and offer advanced stent-based procedures. These markets offer cost-effective services compared to developed nations, making them attractive to foreign patients. This trend has fueled the adoption of bronchoscopy-assisted stenting in both public and private hospitals, creating a strong demand for flexible and hybrid stent designs. Additionally, government health schemes and insurance penetration are facilitating access to high-end procedures, allowing for wider reach among middle- and lower-income groups.

  Medical device manufacturers are also exploring strategic expansions and partnerships in these regions. The relatively lower regulatory barriers and growing physician awareness offer a fertile ground for launching new products and conducting clinical trials. The availability of low-cost manufacturing facilities and skilled labor has further incentivized companies to invest in local production. This helps reduce the cost of stents and improves their accessibility among the general population.

  The ongoing training initiatives for physicians and respiratory specialists are building a more competent medical workforce capable of handling complex respiratory procedures. As local healthcare ecosystems mature, the adoption of lung stents is expected to accelerate, supported by increased diagnosis rates, improving reimbursement policies, and enhanced awareness campaigns. All these factors point to a sustainable growth trajectory for lung stents in emerging healthcare economies.

Restraints

• High cost of stent procedures
• Risk of post-operative complications
• Limited awareness in rural regions

• Stringent regulatory and approval processes -One of the major restraining factors in the lung stents market is the presence of stringent regulatory and approval processes. Regulatory bodies such as the U.S. FDA, EMA, and similar authorities in other regions impose detailed and often time-consuming procedures to ensure the safety and efficacy of lung stents. These requirements often include preclinical testing, clinical trials, and comprehensive risk assessments that can delay product launches. Companies must navigate these complex pathways, which can require years of research and millions in investment before a device can be commercialized.

  Any deviation from established manufacturing protocols, material standards, or patient safety guidelines can lead to rejections, recalls, or legal actions. This discourages smaller firms or startups from entering the market, thereby limiting innovation. Additionally, meeting these regulatory standards often requires extensive documentation and adherence to Good Manufacturing Practices (GMP), which may be challenging for companies operating in low-resource settings.

  Frequent updates to compliance requirements also pose challenges. For instance, changes in clinical evaluation standards or device classification guidelines can lead to the re-evaluation of already-approved products, halting sales or forcing costly redesigns. These changes can also vary by country, making global product expansion even more complex and fragmented. Companies must often hire specialized regulatory consultants to keep up with such evolving landscapes.

  The consequence of these hurdles is a longer time-to-market, increased operational costs, and reduced flexibility in product development. In some cases, companies may even abandon product development due to uncertainties or anticipated regulatory complications. While these standards are critical for ensuring patient safety, they also inadvertently slow innovation and accessibility, particularly in regions that already lack advanced respiratory care options.

Opportunities

• Innovations in bioresorbable stent technology
• Expansion into untapped regional markets
• Growing focus on outpatient procedures

• Collaborations with research and clinical institutes - The lung stents market is witnessing promising growth potential through increased collaborations with research and clinical institutes. These partnerships facilitate the development of next-generation stent technologies, integrating expertise from both academic and industrial spheres. Research institutions bring forth valuable data and prototypes, while medical device companies contribute with funding, manufacturing capabilities, and commercialization channels. Such joint ventures accelerate innovation and improve the practical applicability of lung stents in clinical settings.

  For example, collaborations between hospitals, universities, and device companies have led to the creation of bioabsorbable stents and drug-eluting lung stents, offering better patient outcomes and fewer complications. These developments are aimed at addressing current limitations such as migration, infection, or granulation tissue formation. Research-backed product enhancements are more likely to meet regulatory approvals and gain physician trust, strengthening market positioning.

  Clinical institutes provide real-world testing environments and access to diverse patient populations, which helps in gathering meaningful clinical evidence. This collaboration ensures the devices are optimized not just for regulatory compliance, but also for actual clinical performance and safety. By leveraging these partnerships, companies can conduct faster trials, adapt designs based on feedback, and enter markets with greater confidence.

  Strategic alliances also unlock opportunities for government funding, international grants, and faster ethical clearances for trials. This facilitates early-stage product validation and reduces the financial risk associated with R&D. In the long term, such collaborations will likely lead to more personalized and effective solutions, elevating the overall standards of pulmonary interventional care. These synergies are critical in unlocking the full market potential and achieving scalable innovation.

Key players in Lung Stents Market include:

• Boston Scientific
• C.R. Bard
• Taewoong Medical
• Micro-Tech (Nanjing)
• Teleflex
• Merit Medical Systems
• Cook Group
• Novatech Sa
• Endo-Flex
• M.I. Tech
• Efer Endoscopy
• Fuji Systems

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis